Enlivex Therapeutics (ENLV) Stock Forecast, Price Target & Predictions
ENLV Stock Forecast
Enlivex Therapeutics stock forecast is as follows: an average price target of $15.00 (represents a 1109.68% upside from ENLV’s last price of $1.24) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
ENLV Price Target
The average price target for Enlivex Therapeutics (ENLV) is $15.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $15.00 to $15.00. This represents a potential 1109.68% upside from ENLV's last price of $1.24.
ENLV Analyst Ratings
According to 2 Wall Street analysts, Enlivex Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ENLV stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Enlivex Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 02, 2022 | H.C. Wainwright | $15.00 | $5.69 | 163.62% | 1109.68% |
The latest Enlivex Therapeutics stock forecast, released on May 02, 2022 by H.C. Wainwright company, set a price target of $15.00, which represents a 163.62% increase from the stock price at the time of the forecast ($5.69), and a 1109.68% increase from ENLV last price ($1.24).
Enlivex Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $1.24 | $1.24 | $1.24 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Enlivex Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Enlivex Therapeutics's last price of $1.24. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 27, 2024 | EF Hutton | Buy | Initialise | |
| Jun 11, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Enlivex Therapeutics's last stock rating was published by EF Hutton on Aug 27, 2024. The company Initialise its ENLV rating from "null" to "Buy".
Enlivex Therapeutics Financial Forecast
Enlivex Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Enlivex Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ENLV's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Enlivex Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict ENLV's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Enlivex Therapeutics's previous annual EBITDA (undefined) of $NaN.
Enlivex Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-2.77M | $-2.98M | $-3.40M | $-3.40M | $-3.40M | $-3.40M | $-4.30M |
| High Forecast | $-2.77M | $-2.98M | $-3.40M | $-3.40M | $-3.40M | $-3.40M | $-4.30M |
| Low Forecast | $-2.77M | $-2.98M | $-3.40M | $-3.40M | $-3.40M | $-3.40M | $-4.30M |
| Surprise % | - | - | - | - | - | - | - |
Enlivex Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ENLV's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Enlivex Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Enlivex Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ENLV last annual SG&A of $NaN (undefined).
Enlivex Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.13 | $-0.14 | $-0.16 | $-0.16 | $-0.16 | $-0.16 | $-0.22 |
| High Forecast | $-0.13 | $-0.14 | $-0.16 | $-0.16 | $-0.16 | $-0.16 | $-0.22 |
| Low Forecast | $-0.13 | $-0.14 | $-0.16 | $-0.16 | $-0.16 | $-0.16 | $-0.22 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Enlivex Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ENLV previous annual EPS of $NaN (undefined).
Enlivex Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ENLV | Enlivex Therapeutics | $1.18 | $15.00 | 1171.19% | Buy |
| KROS | Keros Therapeutics | $18.00 | $102.00 | 466.67% | Buy |
| CKPT | Checkpoint Therapeutics | $3.72 | $20.00 | 437.63% | Buy |
| IPSC | Century Therapeutics | $1.17 | $5.00 | 327.35% | Buy |
| PMVP | PMV Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
| CLGN | CollPlant Bio | $3.64 | $12.50 | 243.41% | Buy |
| PPBT | Purple Biotech | $3.92 | $11.00 | 180.61% | |
| ALDX | Aldeyra Therapeutics | $5.33 | $12.00 | 125.14% | Buy |
| MRUS | Merus | $44.90 | $81.25 | 80.96% | Buy |
| CRVS | Corvus Pharmaceuticals | $7.39 | $12.50 | 69.15% | Buy |
| VCEL | Vericel | $56.69 | $57.33 | 1.13% | Buy |